Authored By: Sarah
11 Jul 2024

 Immunohistochemistry Market Size to grow by USD 1.33 billion between 2024-2028

According to a research report “ Immunohistochemistry Market” by Application (Diagnostic application, Research application, Forensic application) End-user (Hospitals and diagnostic laboratories, Academic and research institutes, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1.33 billion, at a CAGR of  8.36% during the forecast period. The global healthcare landscape is confronted with a mounting challenge due to the rising number of cancer patients, which accounted for approximately 10 million deaths in 2020, representing one in every six deaths worldwide. Notable cancer types include breast, lung, colon, rectal, and prostate. In low- and lower-middle-income countries, cancer-inducing infections, such as human papillomavirus (HPV) and hepatitis, contribute to approximately 30% of cancer cases. This escalating cancer prevalence fuels intensified research endeavors to discover novel treatments and elucidate disease mechanisms. Consequently, the burgeoning cancer patient population significantly boosts the demand for immunohistochemistry (IHC) market solutions, which play a pivotal role in diagnosing and understanding cancer progression.

Browse market data tables, figures, and in-depth TOC on “Immunohistochemistry Market” by Application (Diagnostic application, Research application, Forensic application) End-user (Hospitals and diagnostic laboratories, Academic and research institutes, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Application, the Diagnostic application segment is projected to dominate the market size in 2024

In the healthcare industry, the immunohistochemistry market holds significant value due to its crucial role in patient care and disease diagnosis. This technique is instrumental in identifying specific protein markers in tumors, enabling pathologists to determine the origin and characteristics of these growths. Immunohistochemistry plays a vital part in diagnosing and staging various cancers, such as bladder, breast, and colorectal cancer. This information is indispensable for treatment planning and prognosis determination. The shift towards personalized or precision medicine necessitates identifying molecular markers that guide treatment decisions. Immunohistochemistry assists in the identification of these markers, empowering healthcare providers to tailor treatments based on an individual patient's biomolecular profile.

By End-user, Hospitals and diagnostic laboratories  segment is expected to hold the largest market size for the year 2024

In the realm of diagnostics, Immunohistochemistry (IHC) is a pivotal technique, gaining significant traction in pathology and molecular biology. This methodology facilitates the precise localization and visualization of specific proteins or antigens within tissue sections through the application of antibodies that bind to the targeted antigens. IHC plays a vital role in elucidating disease mechanisms, identifying biomarkers, and contributing to accurate patient diagnosis and treatment plans. By detecting disease-specific protein markers, IHC enables personalized therapeutic approaches, enhancing overall patient care and outcomes. As the scientific community continues to unearth novel biomarkers linked to various diseases, the demand for IHC techniques to identify and visualize these markers in tissue samples escalates.

North America is forecasted to hold the largest market size by region in 2024

The immunohistochemistry market in North America is experiencing significant growth due to various factors that reflect the region's advanced healthcare system, robust research capabilities, and dedication to precision medicine. With a well-established healthcare infrastructure comprising numerous hospitals, research institutes, and clinics, North America, particularly the US and Canada, possesses the necessary resources and technology to execute complex diagnostic tests, including immunohistochemistry. This region serves as a global hub for medical research and innovation, with renowned universities, research centers, and pharmaceutical companies leading the charge in developing new diagnostic techniques and therapies. Immunohistochemistry plays a vital role in research initiatives aimed at understanding disease mechanisms and creating targeted treatments.

The Immunohistochemistry Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Agilent Technologies Inc.
  • Bio Rad Laboratories Inc.
  • Bio SB
  • Bio Techne Corp.
  • Biocare Medical LLC
  • BioGenex Laboratories Inc.
  • CANDOR Bioscience GmbH
  • Cell Signaling Technology Inc.
  • Danaher Corp.
  • Eagle Biosciences Inc.
  • Elabscience Biotechnology Inc.
  • F. Hoffmann La Roche Ltd.
  • Lunaphore Technologies SA
  • Merck KGaA
  • Miltenyi Biotec B.V. and Co. KG
  • PerkinElmer Inc
  • PHC Holdings Corp.
  • Takara Holdings Inc.
  • Thermo Fisher Scientific Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Immunohistochemistry (IHC) market is witnessing significant growth due to the increasing incidence of cancer and the need for accurate diagnostic testing. IHC is a laboratory technique used to detect antigens in tissue sections using antibodies. It plays a crucial role in the diagnosis and prognosis of various cancer diseases and infectious diseases. Key players in the market include research organizations, diagnostic laboratories, and companies specializing in IVD equipments and laboratory consumables. The use of IHC in immunofluorescence assays, monoclonal antibodies, and antibody fragments is increasing due to their therapeutic significance in immunotherapy trials. Companies like Roche, Akoya Biosciences, and Leica Biosystems are leading the market with their innovative solutions. Multiplex IHC and digital IHC are the latest trends in the market, offering increased diagnostic accuracy and automation. Healthcare professionals rely on IHC tests for standardization and digital pathology to improve diagnostic efficiency. IHC also plays a vital role in the development of companion diagnostics for personalized medicine. The market is expected to continue growing due to the increasing demand for reliable and accurate diagnostic tools for various diseases.

Market Research Overview

The Immunohistochemistry (IHC) market is witnessing significant growth due to the increasing prevalence of chronic diseases such as Cancer, Stroke, Ischemic heart disease, and Cardiovascular diseases. IHC is a crucial technique in Immunology used for identifying antigens in tissue samples, making it essential in diagnosing various diseases, including infectious diseases like Monkeypox and Viral epidemics. Personalized medicine and therapeutic significance of IHC are gaining prominence in research organizations and diagnostic laboratories. The market for IHC is driven by the rising incidence of Cancer diseases, leading to an increased demand for diagnostic testing and laboratory consumables. Monoclonal antibodies, antibody drugs, and antibody fragments are the key players in the IHC market. Companion diagnostics and reimbursement policies are significant factors influencing the market's growth. Key players in the market include Roche, Akoya Biosciences, and Leica Biosystems, among others. The market is witnessing advancements in technology, with the adoption of digital immunohistochemistry, automation, and multiplex IHC. Healthcare professionals require standardization and IVD equipments for digital pathology and IHC tests to ensure diagnostic accuracy. The geriatric population's growing needs are also fueling the market's growth. The market for IHC is expected to continue its upward trajectory, with significant opportunities in Cancer diseases, Infectious diseases, and Chronic diseases.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!